对先前未治疗的晚期/转移性非小细胞肺癌参与者进行新型免疫治疗组合的第 2 阶段平台研究
一项 2 期、随机、开放标签、平台研究,利用主方案评估新型免疫疗法组合对先前未治疗、局部晚期/转移性、程序性死亡配体 1-选择的非小细胞肺癌参与者的影响
This study will monitor the safety of novel immunotherapy combinations in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells [TC]/ Tumor proportion score [TPS] >= 50%), previously untreated, unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC). Drug name mentioned as Belrestotug, GSK4428859A, and EOS884448 are all interchangeable for the same compound. In the rest of the document, the drug will be referred to as Belrestotug.
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Budapest、匈牙利、H-1121
- GSK Investigational Site
-
Gyöngyös、匈牙利、3200
- GSK Investigational Site
-
Tatabánya、匈牙利、2800
- GSK Investigational Site
-
-
-
-
-
Cape Town、南非、7570
- GSK Investigational Site
-
Parktown、南非、2193
- GSK Investigational Site
-
-
-
-
-
Ankara、土耳其(türkiye)、06800
- GSK Investigational Site
-
Ankara、土耳其(türkiye)、06680
- GSK Investigational Site
-
Antalya、土耳其(türkiye)、07070
- GSK Investigational Site
-
Istanbul、土耳其(türkiye)、34214
- GSK Investigational Site
-
-
Atakum
-
Samsun、Atakum、土耳其(türkiye)、55200
- GSK Investigational Site
-
-
-
-
-
Guadajalara、墨西哥、44280
- GSK Investigational Site
-
San Luis Potosí City、墨西哥、78209
- GSK Investigational Site
-
-
-
-
-
Barretos、巴西、14784-400
- GSK Investigational Site
-
Porto Alegre、巴西、90610-000
- GSK Investigational Site
-
São Paulo、巴西、01246-000
- GSK Investigational Site
-
Vitória、巴西、29043-260
- GSK Investigational Site
-
-
-
-
-
Athens、希腊、11528
- GSK Investigational Site
-
Pylaia Thessaloniki、希腊、57001
- GSK Investigational Site
-
Thessaloniki、希腊、54645
- GSK Investigational Site
-
-
Attica
-
Athens、Attica、希腊、115 27
- GSK Investigational Site
-
Chaïdári、Attica、希腊、124 62
- GSK Investigational Site
-
-
Central Macedonia
-
Thessaloniki、Central Macedonia、希腊、570 10
- GSK Investigational Site
-
-
Thessaly
-
Larissa、Thessaly、希腊、411 10
- GSK Investigational Site
-
-
-
-
-
Berlin、德国、13125
- GSK Investigational Site
-
Heidelberg、德国、69126
- GSK Investigational Site
-
-
North Rhine-Westphalia
-
Essen、North Rhine-Westphalia、德国、45147
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Großhansdorf、Schleswig-Holstein、德国、22927
- GSK Investigational Site
-
-
Thuringia
-
Jena、Thuringia、德国、07747
- GSK Investigational Site
-
-
-
-
-
Avellino、意大利、83100
- GSK Investigational Site
-
Bergamo、意大利、24125
- GSK Investigational Site
-
Pisa、意大利、57124
- GSK Investigational Site
-
Verona、意大利、37045
- GSK Investigational Site
-
-
GE
-
Genova、GE、意大利、16132
- GSK Investigational Site
-
-
-
-
-
Chiba、日本、277-8577
- GSK Investigational Site
-
Fukuoka、日本、812-8582
- GSK Investigational Site
-
Hyōgo、日本、673-8558
- GSK Investigational Site
-
Kanagawa、日本、241-8515
- GSK Investigational Site
-
Osaka、日本、590-0197
- GSK Investigational Site
-
Saitama、日本、350-1298
- GSK Investigational Site
-
-
-
-
-
Wilrijk、比利时、2650
- GSK Investigational Site
-
-
-
-
-
Bordeaux、法国、33076
- GSK Investigational Site
-
Caen、法国、14033
- GSK Investigational Site
-
Marseille、法国、13009
- GSK Investigational Site
-
Quimper、法国、29107
- GSK Investigational Site
-
Strasbourg、法国、67091
- GSK Investigational Site
-
-
-
-
-
Lublin、波兰、20-954
- GSK Investigational Site
-
Prabuty、波兰、82-550
- GSK Investigational Site
-
Siedlce、波兰、08-110
- GSK Investigational Site
-
-
-
-
-
Bangkok、泰国、10210
- GSK Investigational Site
-
Chiang Mai、泰国、50200
- GSK Investigational Site
-
Kho Hong Hat Yai、泰国、90110
- GSK Investigational Site
-
Khon Kaen、泰国、40002
- GSK Investigational Site
-
Pathum Thani、泰国、12120
- GSK Investigational Site
-
-
-
-
Florida
-
Plantation、Florida、美国、33322-5426
- GSK Investigational Site
-
-
New Mexico
-
Albuquerque、New Mexico、美国、87131
- GSK Investigational Site
-
-
Tennessee
-
Chattanooga、Tennessee、美国、37404
- GSK Investigational Site
-
-
West Virginia
-
Morgantown、West Virginia、美国、26506
- GSK Investigational Site
-
-
-
-
-
Oulu、芬兰、90220
- GSK Investigational Site
-
Tampere、芬兰、33520
- GSK Investigational Site
-
Turku、芬兰、20520
- GSK Investigational Site
-
Vaasa、芬兰、65130
- GSK Investigational Site
-
-
-
-
-
Middlesbrough、英国、TS4 3BW
- GSK Investigational Site
-
Wolverhampton、英国、WV10 0QP
- GSK Investigational Site
-
-
Middlesex
-
Northwood、Middlesex、英国、HA6 2RN
- GSK Investigational Site
-
-
-
-
-
Enschede、荷兰、7512 KZ
- GSK Investigational Site
-
Groningen、荷兰、9728 NZ
- GSK Investigational Site
-
Leeuwarden、荷兰、8934 AD
- GSK Investigational Site
-
Utrecht、荷兰、3543 AZ
- GSK Investigational Site
-
-
-
-
-
Guimarães、葡萄牙、4835-044
- GSK Investigational Site
-
Lisbon、葡萄牙、1500-650
- GSK Investigational Site
-
Lisbon、葡萄牙、1998-018
- GSK Investigational Site
-
Porto、葡萄牙、4200-072
- GSK Investigational Site
-
Vila Nova de Gaia、葡萄牙、4434-502
- GSK Investigational Site
-
-
-
-
-
Badajoz、西班牙、06080
- GSK Investigational Site
-
Barcelona、西班牙、08035
- GSK Investigational Site
-
Las Palmas de Gran Canar、西班牙、35016
- GSK Investigational Site
-
Madrid、西班牙、28041
- GSK Investigational Site
-
Madrid、西班牙、28046
- GSK Investigational Site
-
Madrid、西班牙、28027
- GSK Investigational Site
-
Málaga、西班牙、29010
- GSK Investigational Site
-
PamplonaNavarra、西班牙、28027
- GSK Investigational Site
-
Valencia、西班牙、46026
- GSK Investigational Site
-
Valencia、西班牙、46009
- GSK Investigational Site
-
-
Barcelona
-
Badalona、Barcelona、西班牙、08916
- GSK Investigational Site
-
L'Hospitalet de Llobregat、Barcelona、西班牙、08907
- GSK Investigational Site
-
-
-
-
-
Abu Dhabi、阿拉伯联合酋长国
- GSK Investigational Site
-
Abu Dhabi、阿拉伯联合酋长国、51900
- GSK Investigational Site
-
-
-
-
-
Buenos Aires、阿根廷、C1426ABP
- GSK Investigational Site
-
Cipoletti Rio Negro、阿根廷、R8324CVE
- GSK Investigational Site
-
Ciudad Autonoma de Buenos Aire、阿根廷、C1414DRK
- GSK Investigational Site
-
Ciudad Autonoma de Buenos Aire、阿根廷、C1426AGE
- GSK Investigational Site
-
Florida、阿根廷、1602
- GSK Investigational Site
-
Mar del Plata、阿根廷、7600
- GSK Investigational Site
-
San Juan、阿根廷、J5402DIL
- GSK Investigational Site
-
Santa Fe、阿根廷、3000
- GSK Investigational Site
-
-
-
-
-
Incheon、韩国、21565
- GSK Investigational Site
-
Seoul、韩国、03080
- GSK Investigational Site
-
Seoul、韩国、03722
- GSK Investigational Site
-
Suwon Gyeonggi-do、韩国、442-723
- GSK Investigational Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of locally advanced unresectable NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemotherapy or metastatic NSCLC (squamous or non squamous)
- No prior systemic therapy for their locally advanced or metastatic NSCLC
- Provides a fresh tumor tissue sample or archival sample collected within 2 years prior to screening
- PD-L1-high (TC/TPS >= 50%) tumor
- Measurable disease based on RECIST 1.1, as determined by the investigator
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
- Adequate Baseline organ function
- Female participants of childbearing potential must use adequate contraception
Exclusion Criteria:
- Has NSCLC with a tumor that harbors any of the following molecular alterations: EGFR and /or ALK translocations mutations that are sensitive to available targeted inhibitor therapy, Any other known genomic aberrations or oncogenic driver mutations for which a locally approved targeted therapy is available for first-line treatment of locally advanced or metastatic NSCLC.
- Had major surgery within 4 weeks or lung radiation of >30 Gy therapy within 6 months prior to the first dose of study intervention
- Received prior therapy with any immune checkpoint inhibitors
- Never smoked, defined as smoking <100 tobacco cigarettes in a lifetime
- Has an invasive malignancy or history of invasive malignancy other than the disease under study within the last 5 years (clinical exceptions apply as per protocol)
- Symptomatic, untreated, or actively progressing, brain metastases or any leptomeningeal disease (regardless of symptomatology, treatment status, or stability)
- Autoimmune disease or syndrome that required systemic treatment within the past 2 years
- Receiving systemic steroid therapy <= 3 days prior to first dose of study intervention or any form of immunosuppressive medication
- Received any live vaccine <= 30 days prior to first dose of study intervention
- Any history of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis
- History or evidence of cardiac abnormalities
- Current unstable liver or biliary disease
- Severe infection within 4 weeks prior to the first dose of study intervention
- Positive for tuberculosis, human immunodeficiency virus (HIV) infection, hepatitis B surface antigen, or hepatitis C
- Has advanced, symptomatic, or visceral spread and is considered to be at imminent risk of life-threatening complications (including, but not limited to, massive uncontrolled effusions [e.g., pleural, pericardial, peritoneal])
- Is currently participating in or has participated in a study of an investigational therapy within 4 weeks prior to the first dose of study intervention
- Has a history of allogeneic tissue/stem cell transplant or solid organ transplant
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Pembrolizumab Monotherapy
Participants will be administered with pembrolizumab as monotherapy in a fixed dose. |
Pembrolizumab will be administered. |
|
实验性的:Dostarlimab Monotherapy
Participants will be administered with dostarlimab as monotherapy in a fixed dose. |
Dostarlimab will be administered
其他名称:
|
|
实验性的:Substudy 1A
Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose A). |
Belrestotug will be administered.
其他名称:
Dostarlimab will be administered
其他名称:
|
|
实验性的:Substudy 1B
Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose B). |
Belrestotug will be administered.
其他名称:
Dostarlimab will be administered
其他名称:
|
|
实验性的:Substudy 1C
Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose C). |
Belrestotug will be administered.
其他名称:
Dostarlimab will be administered
其他名称:
|
|
实验性的:Substudy 2A
Participants will be administered with dostarlimab, fixed dose belrestotug, and fixed dose nelistotug |
Belrestotug will be administered.
其他名称:
Nelistotug will be administered.
其他名称:
Dostarlimab will be administered
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
接受治疗的不良事件(TEAE)和严重不良事件(SAE)的参与者人数(SAE)
大体时间:长达228周
|
长达228周
|
|
带有TEAES或SAE的参与者数量,导致剂量修改或治疗中断
大体时间:长达228周
|
长达228周
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 213824
- 2021-005115-32 (EudraCT编号)
- GALAXIES LUNG-201 (其他标识符:Study Identifier)
- 2023 (美国 NIH 拨款/合同)
- 2023-505057-40-00 (注册表标识符:CTIS (EU))
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
IPD 共享时间框架
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD 共享访问标准
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.